

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

- Article Title: The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features
- Authors: Roger S. McIntyre, MD; Suresh Durgam, MD; Jason Huo, PhD; Susan G. Kozauer, MD; and Stephen M. Stahl, MD, PhD
- **DOI Number:** 10.4088/JCP.22m14739

List of Supplementary Material for the article

1. <u>Table 1</u> TEAEs Occurring in the Lumateperone Group at ≥5% and More Than Twice the Rate of Placebo

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2023 Physicians Postgraduate Press, Inc.

It is illegal to post this copyrighted PDF on any website. • © 2023 Copyright Physicians Postgraduate Press, Inc.

Supplementary Table 1. TEAEs occurring in the lumateperone group at ≥5% and more than twice the rate of placebo

	With Mixed Features (Baseline YMRS ≥4 and ≤12)		Without Mixed Features (Baseline YMRS <4)	
n (%)	Placebo (n=83)	Lumateperone 42 mg (n=73)	Placebo (n=106)	Lumateperone 42 mg (n=115)
Somnolence	1 (1.2)	11 (15.1)	1 (0.9)	5 (4.3)
Nausea	1 (1.2)	7 (9.6)	3 (2.8)	5 (4.3)
Headache	10 (12.0)	12 (16.4)	9 (8.5)	21 (18.3)
Dizziness postural	0	0	1 (0.9)	8 (7.0)

Abbreviations: TEAE = treatment-emergent adverse event, YMRS = Young Mania Rating Scale.